AS
CRSP icon

Altshuler Shaham’s CRISPR Therapeutics CRSP Stock Holding History

Altshuler Shaham’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10
Closed -$16.2K – 332
2024
Q4 		$16.2K Buy
+10
New +$472 ﹤0.01% 252

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Altshuler Shaham's CRSP Position: Q2 2026 in Review

Altshuler Shaham reduced its CRISPR Therapeutics (CRSP) stake by 100% in Q2 2026, selling an estimated $26.3K and leaving 1 share worth $55. The position accounts for ﹤0.01% of the portfolio, ranked #477.

Altshuler Shaham first reported a position in CRSP in Q1 2021 and has held it in 8 quarters since. The position peaked at $122K in Q1 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Altshuler Shaham held 1 share of CRISPR Therapeutics worth $55 as of Q2 2026.
  • Altshuler Shaham sold 499 CRISPR Therapeutics shares in Q2 2026, an estimated $26.3K.
  • CRISPR Therapeutics made up ﹤0.01% of Altshuler Shaham's portfolio in Q2 2026, its #477 holding.
  • Altshuler Shaham first reported a position in CRISPR Therapeutics in Q1 2021 and has held it in 8 quarters since.
  • Altshuler Shaham's CRISPR Therapeutics position peaked at $122K in Q1 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Altshuler Shaham's 13F filing for Q2 2026, filed 12 Aug 2026.